Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

Immuno-Oncology Survivor Support Resources Where to find reliable information about your condition • American Cancer Society: www.cancer.org • National Cancer Institute: www.cancer.gov • American Society of Clinical Oncology: www.cancer.net • National Comprehensive Cancer Network (NCCN): https://www.nccn.org • National patient advocacy organizations: [See attached for references to …
TREATMENT SUMMARY Name of Patient: Oncologist: Contact Info: DIAGNOSIS Cancer Type/Location/Pathology: Ex. Poorly differentiated carcinoma of the left breast; Ki-67 of 30% Diagnosis Date: Stage: I II III IV Not applicable TREATMENT WITH IMMUNOTHERAPY Names of Agent(s) Used Completion Date: (n/a, if ongoing) Side Effects Experienced • • …
LGBTQI+ communities have a long history of experiencing barriers to healthcare, have increased risk factors for cancer, and are less satisfied with their cancer care. One survey demonstrates that these patients want their providers to show them they are welcome and make that welcome real.
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study Articles 2096 www.thelancet.com Vol 394 December 7, 2019 Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone …
Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma Th e n e w e ngl a nd j o u r na l o f m e dic i n e n engl j med 381;8 nejm.org August 22, 2019 727 The authors’ full names, academic de- grees, and affiliations are listed in the Appendix. Address reprint requests to Dr. Jagannath at the Tisch Cancer Insti- tute, Icahn School of Medicine at Mount …
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study www.thelancet.com/oncology Vol 21 February 2020 207 Articles Lancet Oncol 2020: 21: 207–21 Published Online December 16, 2019 https://doi.org/10.1016/ S1470-2045(19)30788-0 See Comment page 186 Emory University, Winship Cancer Institute, …
Collaborative Physician-Pharmacist–Managed Multiple Myeloma Clinic Improves Guideline Adherence and Prevents Treatment Delays University of Illinois at Chicago, Chicago, IL Corresponding author: Karen Sweiss, PharmD, BCOP, Department of Pharmacy Practice, University of Illinois at Chicago, 833 S. Wood, M/C 886, Chicago IL 60612; e-mail: ksweis2@uic.edu. Disclosures provided by the authors …
SCNCRJTCC3420081307550
• Identify and address challenges in providing care for underserved populations; • Evaluate patient and provider perceptions regarding equity in access to care; • Implement patient-centered approaches to increase guideline-concordant cancer screening among underserved populations; • Develop interventions for promoting guideline-concordant treatment for underserved populations; • Implement …
3, 2, 1, Go! Practical Solutions for Addressing Cancer Care Disparities Equity and Access Committee Roles & Responsibilities To support the 3, 2, 1, Go! project, an Equity and Access Committee will be formed. As a member of the Committee, you—along with other stakeholders from the Hawaii Society of Clinical Oncology (HSCO) and patient advocacy organizations—will oversee the goals of the …
**Highlighted if voted for SB1270 in Committee First Name Last Name Phone Email Facebook Twitter Address Rep. Richard Andrade (D-AZ-29) Richard Andrade 602-926-3130 randrade@azleg.gov 337 1700 W. Washington St. . Phoenix, AZ 85007 Rep. Brenda Barton (R-AZ-6) Brenda Barton 602-926-3421 bbarton@azleg.gov https://twitter.com/Barton4Az 309 1700 W. Washington St. . Phoenix, AZ 85007 Rep. Leo Biasiucci …
Poor access to care among AYA patients is not only evident in low clinical trial enrollment. The struggle to access much-needed care continues when treatment concludes. Most AYA cancer survivors must learn to navigate follow-up medical care on their own.
March 31, 2021
This webinar will help participants better understand the role of laboratory medicine professionals and pathologists in biomarker testing and incorporate a review of testing techniques and applications, lab-specific regulations, and the impact of those regulations on biomarker testing.
Advances in cancer treatment often mean that patients have multiple therapeutic options to choose from. As a result, engagement in decision-making is more important than ever.
SHARED DECISION-MAKING: PRACTICAL IMPLEMENTATION FOR THE ONCOLOGY TEAM Effective Practices for Optimal Patient Engagement TABLE OF CONTENTS Introduction 1 Survey Results: What We Learned 3 Effective Practices in Shared Decision-Making 6 Southern Illinois Healthcare Cancer Institute 6 Levine Cancer Institute, Atrium Health 8 Maine Medical Center Cancer Institute 10 …
Learn about the current clinical applications of liquid biopsies, associated reimbursement issues, and what you can do to implement these tests at your program.
INTRODUCTION A Message from ACCC’s President TOGETHER WE ARE STRONGER 2020 was a year that tested our strength like no other. Overnight, COVID-19 demanded that cancer programs and practices redefine how they work while keeping their patients and staff safe during a global pandemic. As the oncology community addresses these unforeseen changes, there has never been a more important time to …
To help address the ongoing prevalence of colorectal cancer, ACCC is inviting its members to submit proposals for quality improvement initiatives in treating metastatic forms of this cancer.
Dear (Your Colorado Senator), As a healthcare professional who cares for cancer patients, I want to express my opposition to SB21-175 as it is currently written. Those of us who care for cancer patients absolutely support reducing the financial burden on our patients, including medication costs. This bill although well intended, may result in decreased access to lifesaving medications, and default …
þÿ UNEDITED UNREVISED DRAFT 2.23.21 BILL TOPIC: "Prescription Drug Affordability Review Board" DEADLINES: Finalize by: FEB 24, 2021 File by: MAR 2, 2021 First Regular Session Seventy-third General Assembly STATE OF COLORADO DRAFT LLS NO. 21-0497.02 Richard Sweetman x4333 SENATE BILL Senate Committees House Committees A BILL FOR AN ACT 101 CONCERNING THE COLORADO …